Events & Promotions
|
|
GMAT Club Daily Prep
Thank you for using the timer - this advanced tool can estimate your performance and suggest more practice questions. We have subscribed you to Daily Prep Questions via email.
Customized
for You
Track
Your Progress
Practice
Pays
Not interested in getting valuable practice questions and articles delivered to your email? No problem, unsubscribe here.
Sep 0208:00 PM PDT
-09:00 PM PDT
Video explanations + diagnosis of 10 weakest areas + 150+ short videos + study plan!
Sep 0301:30 AM EDT
-02:30 AM EDT
At one point, she believed GMAT wasn’t for her. After scoring 595, self-doubt crept in and she questioned her potential. But instead of quitting, she made the right strategic changes. The result? A remarkable comeback to 695. Check out how Saakshi did it.
Aug 2710:00 AM EDT
-11:00 AM EDT
We’ve worked incredibly hard to build TTP into the best test prep experience possible, and it would mean a lot to us to win Newsweek’s 2026 Readers’ Choice Award for Best Test Prep. If TTP has helped you, we’d be incredibly grateful for your vote.
Sep 0212:30 AM EDT
-01:30 AM EDT
Thought your job leaves no time for GMAT prep? After multiple GMAT attempts and a demanding consulting job, Kshitij improved to 695 in under 2 months. Learn the mindset shifts, study strategy, and execution changes that made the breakthrough possible.
Sep 0201:00 PM EDT
-11:59 PM EDT
Take 30% off all study plans with code COURSEWORK - Expires on Monday 9/7
Sep 0410:00 AM PDT
-11:00 AM PDT
What does test anxiety really look like on the GMAT? For many test takers, it does not look like a panic attack. Instead, it shows up as brain fog, rereading, negative comparisons, mental noise....
Sep 0609:30 AM EDT
-12:30 PM EST
Top scores are possible when you enroll in a powerful EA course, taught live online + 6 months access to TTP OnDemand video courses included! Perfect class schedule and easy course access for working professionals. Class starts Sundays Sept. 6, 2026.- Sep 07
12:01 AM PDT
-11:59 PM PDT
On the 7th, GMAT Club Tests will be Free! Including all the Quizzes, Questions, and Tests. 12 AM - 11:59 PM PDT - Sep 09
07:00 AM PDT
-10:00 AM PDT
Meet AdComs and explore top Master’s programs - MiM, MiF, MSc, MSBA and more. - Application Fee Waivers - Free 1-Week of GMAT Club Tests: - Master's Application Toolkit - Grand Prize Giveaway 
Sep 1507:00 PM EDT
-09:00 PM EST
Elite scores are possible when you enroll in a powerful GMAT course, taught live online + 6 months access to TTP OnDemand video courses included! Class starts Tues/Thurs Sept. 15, 2026 - Nov. 15, 2027, 7:00pm-9:00pm EST
Sep 2108:00 PM EDT
-10:00 PM EDT
Boost your GMAT score in less than one month in a live online class + 6 months access to TTP OnDemand video courses included! Class starts Mon, Tues, Wed, Thur, Fri Sept. 21, 2026 - Oct. 9, 2027, 7:00pm-10:00pm EST
13 Jul 2026, 10:16
Kudos
Bookmarks
The correct option is A. The explanations are as follows:
A - It will weaken the conclusion, which shows it has shown great relief to the patient with the highest initial pain score. Maybe the number of Mild and moderate pain was high, so the average reduction number looks modest, as there won't be much reduction in mild and Moderate pain.
B- Out of scope as it is given that all patients took the full dose with interruption.
C- It will strengthen the author's claim as it is not very effective in reducing pain.
D- Maybe it didn't show initially, but even if it showed later on in the trial period, it will be captured in the calculation of the average reduction of pain. So out of scope
E- It is again strengthing the author's claim that the drug won't be very effective.
A - It will weaken the conclusion, which shows it has shown great relief to the patient with the highest initial pain score. Maybe the number of Mild and moderate pain was high, so the average reduction number looks modest, as there won't be much reduction in mild and Moderate pain.
B- Out of scope as it is given that all patients took the full dose with interruption.
C- It will strengthen the author's claim as it is not very effective in reducing pain.
D- Maybe it didn't show initially, but even if it showed later on in the trial period, it will be captured in the calculation of the average reduction of pain. So out of scope
E- It is again strengthing the author's claim that the drug won't be very effective.
Bunuel
13 Jul 2026, 10:17
Kudos
Bookmarks
Core is : Drug results in modest drop in pain scores. so it's not very effective.
A. No reason or proof of it in the passage so can't be concluded from thin air.
B. All patients completed full dose without interruptions. so cross this.
C. If drug is as effective as placebo then it's not effective.
D. Passage says average pain scores so it takes into consideration overall pain scores during the course of study.
E. My answer: What if drug under experiment performed better than the best available / FDA approved drug. They both have low pain scores but new drug is slightly better.
A. No reason or proof of it in the passage so can't be concluded from thin air.
B. All patients completed full dose without interruptions. so cross this.
C. If drug is as effective as placebo then it's not effective.
D. Passage says average pain scores so it takes into consideration overall pain scores during the course of study.
E. My answer: What if drug under experiment performed better than the best available / FDA approved drug. They both have low pain scores but new drug is slightly better.
13 Jul 2026, 10:31
Kudos
Bookmarks
Conclusion : Drug does not provide any meaningful relief to pain (data shows only modest reduction in pain avergaely)
Assumptions : The pain stays the same during the duration of the trial. The Drug effect is not cumulative. The Analysis and the pain relief data is accurate/reliable
A - Higher pain score => higher pain reduction. This goes against the conclusion that pain drop scores are low
B - patients who took the drug as per schedule reported greater pain reduction. Passage mentions nearly all patients took the drug schedule without interruption and saw only modest pain reduction. It does not weaken the conclusion
C - Placebo => no drug. Drug and no drug have same effect. This strengthens the researchers conclusion
D - Initial pain reduction was negligible but reduction increases during end phase. This could explain why the average Pain reduction is low, but continued dosage would increase the pain reduction making the drug effective. This weakens the researchers conclusion.
E - Other drugs targeting the same pain also have modest pain reductions. This supports the researchers conclusion by saying all the drugs targeting this particular pain have low reductions in pain scores
Answer D
Assumptions : The pain stays the same during the duration of the trial. The Drug effect is not cumulative. The Analysis and the pain relief data is accurate/reliable
A - Higher pain score => higher pain reduction. This goes against the conclusion that pain drop scores are low
B - patients who took the drug as per schedule reported greater pain reduction. Passage mentions nearly all patients took the drug schedule without interruption and saw only modest pain reduction. It does not weaken the conclusion
C - Placebo => no drug. Drug and no drug have same effect. This strengthens the researchers conclusion
D - Initial pain reduction was negligible but reduction increases during end phase. This could explain why the average Pain reduction is low, but continued dosage would increase the pain reduction making the drug effective. This weakens the researchers conclusion.
E - Other drugs targeting the same pain also have modest pain reductions. This supports the researchers conclusion by saying all the drugs targeting this particular pain have low reductions in pain scores
Answer D
